BioSource Completes Acquisition Of Quality Controlled Biochemicals

BioSource International, Inc. has completed its acquisition of Quality Controlled Biochemicals, Inc. (QCB; Hopkinton, MA), announced on Oct. 28, 1998. The purchase of QCB adds over 300 bioactive peptides and 50 antibodies to BioSource's product offerings, with approximately 150 additional antibodies currently under development. Dr. Jordan Fishman, chief scientific officer of QCB, has been retained by BioSource on a three-year employment contract.

James H. Chamberlain, president and CEO of BioSource, believes the acquisition puts his company "squarely within the fields of signal transduction and apoptosis research." He praised Fishman and the QCB staff for their work in developing a catalog of proprietary assay kits, antibodies and bioactive peptides, focused on various aspects of signal transduction, apoptosis and Alzheimer's disease research.

BioSource paid approximately $13.5 million in cash for all of the outstanding capital stock of QCB. For the year ended Dec. 31, 1997, QCB had net revenues of $3.8 million, and for the nine month period ended Sept. 30, 1998, QCB had net revenues of $3.0 million (unaudited).

For more information: BioSource International, Inc., 820 Flynn Rd., Camarillo, CA 93012, USA. Telephone: 805-987-0086.